Iloprost Power 15 in Pulmonary Arterial Hypertension

Inclusion Criteria: * Signed informed consent prior to initiation of any study mandated procedure, * Patients with symptomatic idiopathic, or familial pulmonary arterial hypertension or pulmonary hypertension associated with human immunodeficiency virus (HIV) or drugs/toxins in NYHA functional class II to IV. * Women of childbearing potential must have a negative urine pregnancy test and must use an adequate method of contraception during the study and for 28 days after discontinuation of the study drug. Exclusion Criteria: * Pulmonary arterial hypertension related to any condition other than those specified in the inclusion criteria, * Pulmonary arterial hypertension associated with significant venous or capillary involvement (Pulmonary capillary wedge pressure (PCWP) \> 15 mmHg), * Known pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis, * Moderate to severe obstructive lung disease: forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \< 70% and FEV1 \< 65% of predicted value after bronchodilator administration, * Moderate to severe restrictive lung disease: total lung capacity (TLC) \< 60% of predicted value, * Pregnant or breast-feeding women, * Systemic hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg on repeated measurement), * Systolic blood pressure \< 95 mmHg, * Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C, * Chronic renal insufficiency defined by serum creatinine \> 2.5 mg/dL (221 μmol/L) or ongoing dialysis, * Clinically relevant bleeding disorder or active bleeding, * For those patients on monotherapy, any contraindication to bosentan, ambrisentan, or sildenafil, according to product label, * Known hypersensitivity to iloprost or any of its excipients.